

The SCOUT Study

Short **CO**urse Therapy for **U**rinary **T**ract
Infections in Children

Quick Reference for Physicians



Children's | of
Hospital of Pittsburgh | UPMC

www.chp.edu/scout

412-692-UTIS (8847)

The UTI Center

Inclusion Criteria

- Age $\geq$ 2 months < 10 years
- UTI diagnosis
- Improvement at randomization
 - Afebrile
 - Asymptomatic
- Prescribed:
 - A-C
 - Cefdinir
 - Cefixime
 - Cephalexin
 - TMP-SMX
 - One-time dose of I.M./I.V. abx OK

Exclusion Criteria

- Hospitalization: UTI/ bacteremia/urosepsis/ICU
- Resistant organism
- Cath-associated UTI
- Congenital anomalies
- GU anomalies (other than VUR, duplex, hydronephrosis)
- Can't take P.O. meds
- Previous GU surgery (except for circ)
- Immune deficiency
- Type I hypersensitivity to study product
- Abx study < 30 d prior
- UTI in past 30 d

Key Study Points

What we know

- Abx resolve symptoms
- Abx side effects (diarrhea, diaper rash)
- Overuse – resistant germs
- Shorter courses effective in women
- We don't know whether 5 d instead of 10 d may be all your child needs

Purpose of study

- Short course – less resistance/side effects?
- 700 children at CHP and CHOP
- 5 d vs 10 d of abx; not testing new drug

What will happen

- D 1-5 abx prescribed
- D 6-10 we will provide abx or placebo
 - Random: We don't know; Like having a baby
- 3 visits: enrollment; after tx; at 1 month
- Urine tested after tx, bag specimen
- Stool tested each visit for resistant germs
- Close monitoring; 24/7 availability